Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. In premarketing clinical trials, 54% of patients experienced neuropathy of any grade. Of these patients, 49% had complete resolution, 31% had partial improvement, and 20% had no improvement. A total of 51% of patients who reported neuropathy had residual neuropathy at the time of their last evaluation.

MANAGEMENT: The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.